capecitabine + gemcitabine + erlotinib + bevacizumab

A four-drug antineoplastic regimen combining two cytotoxic fluoropyrimidine/nucleoside analogs (capecitabine, gemcitabine) with a small‑molecule epidermal growth factor receptor inhibitor (erlotinib) and an anti‑VEGF monoclonal antibody (bevacizumab). Capecitabine is an oral prodrug of 5‑fluorouracil that inhibits thymidylate synthase and interferes with DNA synthesis. Gemcitabine is a deoxycytidine analog that inhibits DNA synthesis and ribonucleotide reductase. Erlotinib is an oral EGFR tyrosine kinase inhibitor that blocks downstream signaling to reduce tumor cell proliferation and survival. Bevacizumab is an intravenous humanized IgG1 antibody targeting VEGF‑A to inhibit angiogenesis. The combination has been explored in oncology to synergize cytotoxic chemotherapy with targeted blockade of EGFR signaling and tumor angiogenesis; bevacizumab’s approved indications include multiple solid tumors when combined with specific chemotherapies, reflecting its anti‑angiogenic role.

Other names

XELODA + GEMZAR + TARCEVA + Avastin